Healthy
Conditions
Keywords
Bioequivalence, Lamotrigine Extended Release, crossover
Brief summary
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study.
Detailed description
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study of Lamotrigine Extended Release tablets 200mg of Dr. Reddy's Laboratories Limited, India comparing with that of LAMICTAL XR(containing Lamotrigine) Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC in healthy, adult, human subjects under fed conditions.
Interventions
DRUGLamotrigine
Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Sponsors
Dr. Reddy's Laboratories Limited
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects were selected based on the following inclusion criteria: * Provide written informed consent. * Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive) weighing at least 50 kg. * Having a body mass index between 18.5 and 24.9 (both inclusive), calculated as weight in Kg/height in m 2. * Must be of normal health as determined by medical history, physical examination and laboratory investigation performed within 28 days prior to the commencement of the study. (Laboratory values must be within normal limits or considered by the physician / investigator to be of no clinical significance). * Female Subjects * Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence. * Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)
Exclusion criteria
The subjects were excluded based on the following criteria during screening and during the study: * Incapable of understanding the informed consent. * Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg. * Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg. * Oral temperature is below 95.0°F or above 98.6°F. * Pulse rate below 50/min or above 100/min. * History of hypersensitivity or idiosyncratic reaction to investigational drug product or any other related drugs or its ingredients. * Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function. * Consumption of grapefruit for the past ten days prior to the check-in, in each period. * Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking during sample collection period. * Habit of tobacco chewing. * Habit of alcoholism and difficulty in abstaining from alcohol during the sample collection period. * Difficulty in abstaining from xanthine containing food or beverages (like tea, coffee, chocolates and cola drinks) during the sample collection period. * Intake of over the counter (OTC) or prescribed medications and enzyme modifying medication or systemic medication for the last 30 days before dosing. * Clinically significant abnormalities and / or with significant diseases. * Confirmed positive in alcohol screening. * Confirmed positive in urine cotinine test. * Confirmed positive in selected drug of abuse. * Participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study. * Confirmed positive in urine pregnancy test. xx. Female detected to be pregnant, breast feeding or who is likely to become pregnant during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under curve(AUC) | Blood samples were withdrawn at predose (0.00) and 1.00, 2.00, 3.00, 4.50, 6.00, 7.50, 9.00, 10.50, 12.00, 13.50, 15.00, 16.50, 18.00, 20.00, 22.00, 24.00, 26.00, 30.00, 36.00, 48.00, 72.00, 96.00, 120.00, 144.00 and 168.00 hours post-dose. |
Countries
India
Outcome results
None listed